Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
Androgen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and (in a substantial minority of cases) neuroendocri...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0287126 |
| _version_ | 1797659875907469312 |
|---|---|
| author | Rolando D Z Lyles Maria J Martinez Benjamin Sherman Stephan Schürer Kerry L Burnstein |
| author_facet | Rolando D Z Lyles Maria J Martinez Benjamin Sherman Stephan Schürer Kerry L Burnstein |
| author_sort | Rolando D Z Lyles |
| collection | DOAJ |
| description | Androgen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and (in a substantial minority of cases) neuroendocrine prostate cancer (NEPC) is common. Identifying effective targeted therapies is challenging because of acquired resistance to established treatments and the vast heterogeneity of advanced prostate cancer (PC). To streamline the identification of potentially active prostate cancer therapeutics, we have developed an adaptable semi-automated protocol which optimizes cell growth and leverages automation to enhance robustness, reproducibility, and throughput while integrating live-cell imaging and endpoint viability assays to assess drug efficacy in vitro. In this study, culture conditions for 72-hr drug screens in 96-well plates were established for a large, representative panel of human prostate cell lines including: BPH-1 and RWPE-1 (non-tumorigenic), LNCaP and VCaP (ADPC), C4-2B and 22Rv1 (CRPC), DU 145 and PC3 (androgen receptor-null CRPC), and NCI-H660 (NEPC). The cell growth and 72-hr confluence for each cell line was optimized for real-time imaging and endpoint viability assays prior to screening for novel or repurposed drugs as proof of protocol validity. We demonstrated effectiveness and reliability of this pipeline through validation of the established finding that the first-in-class BET and CBP/p300 dual inhibitor EP-31670 is an effective compound in reducing ADPC and CRPC cell growth. In addition, we found that insulin-like growth factor-1 receptor (IGF-1R) inhibitor linsitinib is a potential pharmacological agent against highly lethal and drug-resistant NEPC NCI-H660 cells. This protocol can be employed across other cancer types and represents an adaptable strategy to optimize assay-specific cell growth conditions and simultaneously assess drug efficacy across multiple cell lines. |
| first_indexed | 2024-03-11T18:22:36Z |
| format | Article |
| id | doaj.art-dcf70f64566a4e93901e812ee8157e56 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-11T18:22:36Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-dcf70f64566a4e93901e812ee8157e562023-10-15T05:32:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-011810e028712610.1371/journal.pone.0287126Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.Rolando D Z LylesMaria J MartinezBenjamin ShermanStephan SchürerKerry L BurnsteinAndrogen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and (in a substantial minority of cases) neuroendocrine prostate cancer (NEPC) is common. Identifying effective targeted therapies is challenging because of acquired resistance to established treatments and the vast heterogeneity of advanced prostate cancer (PC). To streamline the identification of potentially active prostate cancer therapeutics, we have developed an adaptable semi-automated protocol which optimizes cell growth and leverages automation to enhance robustness, reproducibility, and throughput while integrating live-cell imaging and endpoint viability assays to assess drug efficacy in vitro. In this study, culture conditions for 72-hr drug screens in 96-well plates were established for a large, representative panel of human prostate cell lines including: BPH-1 and RWPE-1 (non-tumorigenic), LNCaP and VCaP (ADPC), C4-2B and 22Rv1 (CRPC), DU 145 and PC3 (androgen receptor-null CRPC), and NCI-H660 (NEPC). The cell growth and 72-hr confluence for each cell line was optimized for real-time imaging and endpoint viability assays prior to screening for novel or repurposed drugs as proof of protocol validity. We demonstrated effectiveness and reliability of this pipeline through validation of the established finding that the first-in-class BET and CBP/p300 dual inhibitor EP-31670 is an effective compound in reducing ADPC and CRPC cell growth. In addition, we found that insulin-like growth factor-1 receptor (IGF-1R) inhibitor linsitinib is a potential pharmacological agent against highly lethal and drug-resistant NEPC NCI-H660 cells. This protocol can be employed across other cancer types and represents an adaptable strategy to optimize assay-specific cell growth conditions and simultaneously assess drug efficacy across multiple cell lines.https://doi.org/10.1371/journal.pone.0287126 |
| spellingShingle | Rolando D Z Lyles Maria J Martinez Benjamin Sherman Stephan Schürer Kerry L Burnstein Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. PLoS ONE |
| title | Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. |
| title_full | Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. |
| title_fullStr | Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. |
| title_full_unstemmed | Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. |
| title_short | Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. |
| title_sort | automation live cell imaging and endpoint cell viability for prostate cancer drug screens |
| url | https://doi.org/10.1371/journal.pone.0287126 |
| work_keys_str_mv | AT rolandodzlyles automationlivecellimagingandendpointcellviabilityforprostatecancerdrugscreens AT mariajmartinez automationlivecellimagingandendpointcellviabilityforprostatecancerdrugscreens AT benjaminsherman automationlivecellimagingandendpointcellviabilityforprostatecancerdrugscreens AT stephanschurer automationlivecellimagingandendpointcellviabilityforprostatecancerdrugscreens AT kerrylburnstein automationlivecellimagingandendpointcellviabilityforprostatecancerdrugscreens |